FDA inspectors found bugs, mold and a scramble to dump samples at two Chinese plants making ingredients for unapproved weight-loss drugs, and put both firms on an import ban list.
The New York Post reported that Food and Drug Administration inspectors documented “gross contamination” at facilities run by Chengdu Shengnuo Biopharm Co and Nanjing Chengong Pharmaceutical Co, which make components used in copycat versions of blockbuster GLP-1 weight-loss drugs.
Those active ingredients, semaglutide and tirzepatide, power the big-name shots from Novo Nordisk and Eli Lilly. The Chinese plants were tied to compounding pharmacies turning out versions not approved for sale by safety regulators, Bloomberg reported in coverage carried by the Post.
Both companies landed on the FDA’s import list. That means their products can be seized at the border. The finished drugs themselves were never tested.
At the Chengdu Shengnuo Biopharm Co site, inspectors found bugs in the ceiling and moldy floors. When the U.S. team arrived, workers were pouring product samples into sinks in what the report called a “seemingly coordinated effort.”
Staff also rushed documents out of a lab, carried them across the hall, and stuffed them into lockers. Inspectors could not recover everything. Those details came from records obtained under a Freedom of Information Act request.
Chengdu Shengnuo told China’s government in a filing that it has been “diligently implementing effective measures” to fix the problems. The Post said it reached out to both Chinese labs and the FDA; none gave an immediate response.
"diligently implementing effective measures"
That was the company’s public line after the inspection findings surfaced.
Conditions at the Nanjing Chengong Pharmaceutical Co factory raised a different red flag. Staff had been buying active ingredients made by other factories and applying Nanjing Chengong’s own seal of approval, without reviewing the testing and safety paperwork.
In plain terms, the company was putting its name on material it had not properly checked. That is the kind of shortcut that turns a supply chain into a gamble for patients.
Michael Rogers, a former FDA investigator, did not mince words about what the inspection picture showed.
"suggest a serious accident waiting to happen."
Rogers gave that assessment to Bloomberg after reviewing the reported findings.
Compounded versions of these drugs sit inside a much larger trade. The Wall Street Journal has described compounded drugs as part of a multibillion-dollar industry of unregulated peptides, custom-mixed products that often sit outside the normal brand-name safety lane.
Some overseas compounding operations run on the theory that U.S. law lets them sell copycat peptides. The FDA is now weighing whether to allow compounding pharmacies abroad to produce more of these products. Health Secretary Robert F. Kennedy, who oversees the FDA, has supported lifting restrictions on peptides.
That policy debate collides with what inspectors found in China: mold, insects, dumped samples, missing documents, and seals applied without safety review. The import-list action stops product at the border. It does not rewrite the incentives that built this shadow market in the first place.
Nearly fifteen years ago, contaminated drugs from the New England Compounding Pharmacy, including a steroid shot for pain, infected more than 700 people with meningitis and killed 64. That disaster is the clearest modern reminder of what happens when sterile manufacturing standards collapse.
GLP-1 drugs are now mass-market medicine. Millions of Americans use them or want them. When demand outruns approved supply, gray-market and compounded alternatives rush in. Factories that hide records and skip documentation are not a footnote in that story. They are the risk.
Inspectors did not claim these two plants had already harmed patients. They did document conditions and conduct that have no place in a drug supply chain. Bugs in a ceiling and mold on a floor are not paperwork disputes. Neither is pouring samples down a sink as the inspection team walks in.
Americans chasing weight-loss treatments deserve ingredients made under rules that put safety first, not seals stamped on unchecked powder and facilities that scramble when the FDA shows up. Clean medicine is not optional, and neither is enforcing it before the next preventable disaster.